美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Polyrizon Ltd.

13.25

+0.40503.15%

盤後：13.21-0.0400-0.30%19:44 EST

成交量：6.03萬

成交額：77.57萬

市值：1,380.25萬

市盈率：-18.62

高：13.46

開：13.19

低：12.03

收：12.85

52周最高：2,235.00

52周最低：2.88

股本：104.17萬

流通股本：99.68萬

量比：0.45

換手率：6.05%

股息：- -

股息率：- -

每股收益(TTM):-0.7114

淨資產收益率：-12.20%

總資產收益率：-22.25%

市淨率：0.75

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

Polyrizon與合作伙伴達成協議，共同開發專有非致幻性神經可塑性藥物鼻腔製劑

Clearmind Medicine簽署開發協議，推進其專有無致幻神經塑性藥物Meai的鼻內製劑研發

Polyrizon Ltd.股價飆升12.25% 市值漲164.86萬美元

Polyrizon啓動Nasarix™過敏阻斷劑可用性研究項目，推進監管審批進程

Polyrizon Ltd. 董事會批准進行選擇性投資，預計將產生近期收益

Polyrizon Ltd. 初期戰略聚焦高潛力領域運營公司，涵蓋國防、航空及人工智能

Polyrizon 向 FDA 提交 PL-16 病毒阻斷劑的前期指定請求，旨在減少對流感和感冒病毒的暴露

Polyrizon宣佈良好的滲透動力學，支持其鼻用納洛酮水凝膠項目的推進

Polyrizon發布與市場上市的鼻用納洛酮產品相比的積極粘附性結果

Polyrizon宣佈按1至6的比例進行普通股反向拆分 - SEC文件

Polyrizon Ltd.盤中異動股價大跌6.41%報0.721美元

Polyrizon Ltd.公布積極的臨牀前研究結果：Pl-14顯示出令人鼓舞的過敏原阻斷效果

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/PLRZ/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PLRZ","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PLRZ\",,,,,undefined,":{"symbol":"PLRZ","market":"US","secType":"STK","nameCN":"Polyrizon Ltd.","latestPrice":13.25,"timestamp":1770670800000,"preClose":12.845,"halted":0,"volume":60324,"hourTrading":{"tag":"盘后","latestPrice":13.21,"preClose":13.25,"latestTime":"19:44 EST","volume":2544,"amount":33612.12,"timestamp":1770684287137,"change":-0.04,"changeRate":-0.003019,"amplitude":0.022642},"delay":0,"changeRate":0.03152977812378352,"floatShares":996800,"shares":1041700,"eps":-0.71144193,"marketStatus":"已收盤","change":0.405,"latestTime":"02-09 16:00:00 EST","open":13.19,"high":13.46,"low":12.0301,"amount":775667.226048,"amplitude":0.11132,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.71144193,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1770714000000},"marketStatusCode":5,"adr":0,"listingDate":1730174400000,"exchange":"NASDAQ","adjPreClose":12.845,"preHourTrading":{"tag":"盘前","latestPrice":12.86,"preClose":12.83,"latestTime":"09:06 EST","volume":117,"amount":1528.838883,"timestamp":1770646017706,"change":0.03,"changeRate":0.002338,"amplitude":0.091972},"postHourTrading":{"tag":"盘后","latestPrice":13.21,"preClose":13.25,"latestTime":"19:44 EST","volume":2544,"amount":33612.12,"timestamp":1770684287137,"change":-0.04,"changeRate":-0.003019,"amplitude":0.022642},"volumeRatio":0.450774},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PLRZ\",,,,,undefined,":{"symbol":"PLRZ","floatShares":996800,"roa":"-22.25%","roe":"-12.20%","lyrEps":0,"volumeRatio":0.450774,"shares":1041700,"dividePrice":0,"high":13.46,"amplitude":0.11132,"preClose":12.845,"low":12.0301,"week52Low":2.88,"pbRate":"0.75","week52High":2235,"institutionHeld":0,"latestPrice":13.25,"eps":-0.71144193,"divideRate":0,"volume":60324,"delay":0,"ttmEps":-0.71144193,"open":13.19,"prevYearClose":8.49,"prevWeekClose":12.845,"prevMonthClose":11.51,"prevQuarterClose":8.49,"fiveDayClose":15.12,"twentyDayClose":12.79,"sixtyDayClose":5.1066},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PLRZ\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-11-28","symbol":"PLRZ","defaultRemindTime":1764340200000,"type":"split","dateTimestamp":1764306000000,"forFactor":6,"toFactor":1,"ratio":6},{"market":"US","date":"2025-05-27","symbol":"PLRZ","defaultRemindTime":1748352600000,"type":"split","dateTimestamp":1748318400000,"forFactor":250,"toFactor":1,"ratio":250}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PLRZ\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PLRZ\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/PLRZ\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"PLRZ","date":"2026-02-06","current":-18.624148,"percent":0.107256,"low":-29.515607,"twenty":-11.383325,"median":-5.167341,"eighty":-1.959036,"high":-0.011381,"avg":-7.11177,"sd":6.228146,"marketCap":19812748},"quantilePoints":[{"date":"2024-10-31","current":-13.097935,"twenty":-22.948538,"median":-13.097935,"eighty":-12.489816,"marketCap":7858761},{"date":"2024-11-08","current":-3.903419,"twenty":-12.692522,"median":-4.690878,"eighty":-4.316449,"marketCap":3891709},{"date":"2024-11-15","current":-2.661127,"twenty":-9.219549,"median":-4.249136,"eighty":-3.530862,"marketCap":2653144},{"date":"2024-11-22","current":-2.985655,"twenty":-4.737156,"median":-3.736612,"eighty":-3.09924,"marketCap":2976698},{"date":"2024-11-29","current":-3.042447,"twenty":-4.451075,"median":-3.375089,"eighty":-3.037515,"marketCap":3033320},{"date":"2024-12-06","current":-3.212824,"twenty":-4.383762,"median":-3.342636,"eighty":-3.042447,"marketCap":3203186},{"date":"2024-12-13","current":-3.375088,"twenty":-4.191157,"median":-3.358862,"eighty":-3.047315,"marketCap":3364963},{"date":"2024-12-20","current":-7.561496,"twenty":-4.383762,"median":-3.375088,"eighty":-3.07146,"marketCap":7538812},{"date":"2024-12-27","current":-5.744141,"twenty":-5.095085,"median":-3.407542,"eighty":-3.090153,"marketCap":5726909},{"date":"2025-01-03","current":-5.938858,"twenty":-6.101122,"median":-3.569805,"eighty":-3.132991,"marketCap":5921041},{"date":"2025-01-10","current":-4.997727,"twenty":-6.159537,"median":-3.796975,"eighty":-3.146231,"marketCap":4982734},{"date":"2025-01-17","current":-6.142316,"twenty":-6.098128,"median":-3.933764,"eighty":-3.167391,"marketCap":6123889},{"date":"2025-01-24","current":-5.889893,"twenty":-6.192801,"median":-4.333277,"eighty":-3.193353,"marketCap":5872223},{"date":"2025-01-31","current":-5.553327,"twenty":-6.125488,"median":-4.527162,"eighty":-3.214122,"marketCap":5536667},{"date":"2025-02-07","current":-4.552045,"twenty":-6.087615,"median":-4.738105,"eighty":-3.227753,"marketCap":4538389},{"date":"2025-02-14","current":-4.711914,"twenty":-6.064471,"median":-4.705652,"eighty":-3.245278,"marketCap":4697778},{"date":"2025-02-21","current":-4.522596,"twenty":-6.049761,"median":-4.627772,"eighty":-3.258259,"marketCap":4509028},{"date":"2025-02-28","current":-3.707687,"twenty":-6.000655,"median":-4.535397,"eighty":-3.316674,"marketCap":3696564},{"date":"2025-03-07","current":-3.460732,"twenty":-5.929065,"median":-4.501561,"eighty":-3.241954,"marketCap":3450350},{"date":"2025-03-14","current":-1.846098,"twenty":-5.873065,"median":-4.396383,"eighty":-3.213473,"marketCap":2852222},{"date":"2025-03-21","current":-1.508371,"twenty":-5.793429,"median":-4.291207,"eighty":-3.160314,"marketCap":2330433},{"date":"2025-03-28","current":-1.353625,"twenty":-5.705978,"median":-3.977976,"eighty":-3.07146,"marketCap":2091350},{"date":"2025-04-04","current":-0.974631,"twenty":-5.536499,"median":-3.903419,"eighty":-3.030526,"marketCap":1505805},{"date":"2025-04-11","current":-0.980061,"twenty":-5.4398,"median":-3.702849,"eighty":-2.640357,"marketCap":1514194},{"date":"2025-04-17","current":-0.985491,"twenty":-5.322255,"median":-3.619184,"eighty":-1.846098,"marketCap":1522583},{"date":"2025-04-25","current":-0.947483,"twenty":-5.174691,"median":-3.5049,"eighty":-1.520317,"marketCap":1463861},{"date":"2025-05-02","current":-0.687943,"twenty":-5.159991,"median":-3.434137,"eighty":-1.353625,"marketCap":1062872},{"date":"2025-05-09","current":-2.602277,"twenty":-5.095085,"median":-3.375088,"eighty":-1.466019,"marketCap":4020518},{"date":"2025-05-16","current":-0.039201,"twenty":-5.02132,"median":-3.354145,"eighty":-1.299871,"marketCap":60566},{"date":"2025-05-23","current":-0.018499,"twenty":-5.006408,"median":-3.310183,"eighty":-1.057434,"marketCap":28581},{"date":"2025-05-30","current":-0.022023,"twenty":-4.999463,"median":-3.245278,"eighty":-1.021327,"marketCap":34025},{"date":"2025-06-06","current":-0.014912,"twenty":-4.937359,"median":-3.214447,"eighty":-0.978975,"marketCap":23039},{"date":"2025-06-13","current":-0.018851,"twenty":-4.922267,"median":-3.183486,"eighty":-0.945854,"marketCap":29125},{"date":"2025-06-20","current":-0.013358,"twenty":-4.871782,"median":-3.155299,"eighty":-0.895899,"marketCap":20638},{"date":"2025-06-27","current":-2.431375,"twenty":-4.817057,"median":-3.116926,"eighty":-0.895899,"marketCap":3756474},{"date":"2025-07-03","current":-2.428961,"twenty":-4.79003,"median":-3.054617,"eighty":-0.90676,"marketCap":3752744},{"date":"2025-07-11","current":-2.469311,"twenty":-4.75787,"median":-3.036282,"eighty":-0.929565,"marketCap":3815085},{"date":"2025-07-18","current":-3.343916,"twenty":-4.728069,"median":-3.039365,"eighty":-0.942596,"marketCap":5166350},{"date":"2025-07-25","current":-4.793774,"twenty":-4.784488,"median":-3.066787,"eighty":-0.954976,"marketCap":7406381},{"date":"2025-08-01","current":-9.134632,"twenty":-4.922267,"median":-3.137242,"eighty":-0.969039,"marketCap":14113006},{"date":"2025-08-08","current":-8.476938,"twenty":-5.004125,"median":-3.155299,"eighty":-0.973817,"marketCap":13096869},{"date":"2025-08-15","current":-8.18463,"twenty":-5.134029,"median":-3.19779,"eighty":-0.976803,"marketCap":12645253},{"date":"2025-08-22","current":-7.746168,"twenty":-5.410414,"median":-3.21607,"eighty":-0.982233,"marketCap":11967829},{"date":"2025-08-29","current":-7.600014,"twenty":-5.856236,"median":-3.245278,"eighty":-0.987228,"marketCap":11742021},{"date":"2025-09-05","current":-7.819245,"twenty":-6.049761,"median":-3.325781,"eighty":-0.992223,"marketCap":12080733},{"date":"2025-09-12","current":-7.143282,"twenty":-6.209629,"median":-3.343916,"eighty":-1.006667,"marketCap":11036370},{"date":"2025-09-19","current":-10.354516,"twenty":-6.696876,"median":-3.375088,"eighty":-1.026648,"marketCap":11742021},{"date":"2025-09-26","current":-11.070023,"twenty":-7.035762,"median":-3.443585,"eighty":-1.030557,"marketCap":12553406},{"date":"2025-10-03","current":-11.383325,"twenty":-7.364852,"median":-3.487865,"eighty":-1.042883,"marketCap":12908691},{"date":"2025-10-10","current":-13.054272,"twenty":-7.512322,"median":-3.569805,"eighty":-1.058791,"marketCap":14803545},{"date":"2025-10-17","current":-11.174457,"twenty":-7.59231,"median":-3.644879,"eighty":-1.068565,"marketCap":12671834},{"date":"2025-10-24","current":-11.278891,"twenty":-7.731553,"median":-3.707687,"eighty":-1.123948,"marketCap":12790262},{"date":"2025-10-31","current":-10.75672,"twenty":-7.950784,"median":-3.905854,"eighty":-1.280758,"marketCap":12198121},{"date":"2025-11-07","current":-9.567215,"twenty":-8.038476,"median":-3.996712,"eighty":-1.310622,"marketCap":10849222},{"date":"2025-11-14","current":-8.045608,"twenty":-8.360015,"median":-4.312242,"eighty":-1.376104,"marketCap":9123720},{"date":"2025-11-21","current":-6.109399,"twenty":-8.170015,"median":-4.417419,"eighty":-1.474489,"marketCap":6928059},{"date":"2025-11-28","current":-5.587228,"twenty":-8.111553,"median":-4.501561,"eighty":-1.508371,"marketCap":6335917},{"date":"2025-12-05","current":-25.23826,"twenty":-8.403861,"median":-4.535397,"eighty":-1.515701,"marketCap":28620187},{"date":"2025-12-12","current":-21.591766,"twenty":-8.696169,"median":-4.627772,"eighty":-1.520317,"marketCap":24485063},{"date":"2025-12-19","current":-17.597159,"twenty":-9.06593,"median":-4.711914,"eighty":-1.541633,"marketCap":19955178},{"date":"2025-12-26","current":-13.245735,"twenty":-9.27961,"median":-4.754698,"eighty":-1.546299,"marketCap":15020663},{"date":"2026-01-02","current":-14.777436,"twenty":-10.201257,"median":-4.798393,"eighty":-1.579229,"marketCap":16757612},{"date":"2026-01-09","current":-23.341039,"twenty":-10.662157,"median":-4.922267,"eighty":-1.630419,"marketCap":26468738},{"date":"2026-01-16","current":-21.842963,"twenty":-11.038692,"median":-4.999213,"eighty":-1.702674,"marketCap":24769920},{"date":"2026-01-23","current":-22.02569,"twenty":-11.165081,"median":-5.003554,"eighty":-1.780942,"marketCap":24977133},{"date":"2026-01-30","current":-18.441421,"twenty":-11.278891,"median":-5.035187,"eighty":-1.871075,"marketCap":20912571},{"date":"2026-02-06","current":-17.471559,"twenty":-11.383325,"median":-5.167341,"eighty":-1.959036,"marketCap":19812748}],"updateTime":1770692354093},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PLRZ\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1183826025","title":"Polyrizon與合作伙伴達成協議，共同開發專有非致幻性神經可塑性藥物鼻腔製劑","url":"https://stock-news.laohu8.com/highlight/detail?id=1183826025","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1183826025?lang=zh_tw&edition=fundamental","pubTime":"2026-02-06 20:56","pubTimestamp":1770382574,"startTime":"0","endTime":"0","summary":"生物医药公司Polyrizon Ltd.近日宣布，已签署一项重要合作协议，旨在推进其专有的非致幻性神经可塑性药物（Neuroplastogen）鼻腔制剂的研发进程。该合作标志着公司在创新神经科学疗法领域迈出了关键一步。\n此次开发的鼻腔制剂采用了独特的技术路径，旨在通过鼻内给药方式靶向神经系统，促进神经可塑性，同时避免了传统精神活性物质常见的致幻副作用。这一特性使其在治疗抑郁症、创伤后应激障碍等神经系统相关疾病方面具有广阔的临床应用潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMND","PLRZ","BK4007"],"gpt_icon":0},{"id":"1173106061","title":"Clearmind Medicine簽署開發協議，推進其專有無致幻神經塑性藥物Meai的鼻內製劑研發","url":"https://stock-news.laohu8.com/highlight/detail?id=1173106061","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1173106061?lang=zh_tw&edition=fundamental","pubTime":"2026-02-06 20:56","pubTimestamp":1770382573,"startTime":"0","endTime":"0","summary":"Clearmind Medicine Inc. 近日与Polyrizon Ltd. 达成一项开发合作协议，旨在加速其专有无致幻神经塑性化合物Meai的鼻内制剂研发进程。该合作将结合Clearmind在神经科学领域的专长与Polyrizon在药物递送技术方面的优势，共同推进新型治疗方案的开发。此次合作标志着公司在非致幻性神经可塑性药物研发领域迈出重要一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLRZ","CMND","BK4007"],"gpt_icon":0},{"id":"2608582476","title":"Polyrizon Ltd.股價飆升12.25% 市值漲164.86萬美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2608582476","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608582476?lang=zh_tw&edition=fundamental","pubTime":"2026-02-02 22:35","pubTimestamp":1770042902,"startTime":"0","endTime":"0","summary":"北京时间2026年02月02日22时35分，Polyrizon Ltd.股票出现波动，股价急速上涨12.25%。截至发稿，该股报12.92美元/股，成交量1.5876万股，换手率1.52%，振幅4.17%。Polyrizon Ltd.股票所在的生物技术行业中，整体跌幅为0.05%。其相关个股中，60 Degrees Pharmaceuticals Inc C/Wts 12/07/2028 、Polyrizon Ltd.、Verrica制药涨幅较大，60 Degrees Pharmaceuticals, Inc.、Vivosim Labs, Inc.、Vyome Holdings, Inc.较为活跃，换手率分别为248.27%、17.03%、14.96%，振幅较大的相关个股有Bioatla, Inc.、Context Therapeutics Inc.、天演药业，振幅分别为27.73%、18.39%、15.27%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260202223502a6cab6b9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260202223502a6cab6b9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PLRZ"],"gpt_icon":0},{"id":"1117300089","title":"Polyrizon啓動Nasarix™過敏阻斷劑可用性研究項目，推進監管審批進程","url":"https://stock-news.laohu8.com/highlight/detail?id=1117300089","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1117300089?lang=zh_tw&edition=fundamental","pubTime":"2026-01-22 22:27","pubTimestamp":1769092073,"startTime":"0","endTime":"0","summary":"Polyrizon有限公司在推进其主打产品Nasarix™过敏阻断剂的监管审批道路上迈出了关键一步，正式启动了该产品的可用性研究项目。这一举措旨在评估产品的实际使用体验与性能，为后续向监管机构提交申请收集必要的数据支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLRZ"],"gpt_icon":0},{"id":"1108909694","title":"Polyrizon Ltd. 董事會批准進行選擇性投資，預計將產生近期收益","url":"https://stock-news.laohu8.com/highlight/detail?id=1108909694","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1108909694?lang=zh_tw&edition=fundamental","pubTime":"2026-01-13 21:46","pubTimestamp":1768311997,"startTime":"0","endTime":"0","summary":"Polyrizon Ltd. 宣布，其董事会已正式批准一项战略计划，将着手进行一系列选择性投资。公司方面表示，这些经过精心筛选的投资项目，预计将在短期内为公司带来可观的收入增长。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLRZ"],"gpt_icon":0},{"id":"1176001861","title":"Polyrizon Ltd. 初期戰略聚焦高潛力領域運營公司，涵蓋國防、航空及人工智能","url":"https://stock-news.laohu8.com/highlight/detail?id=1176001861","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1176001861?lang=zh_tw&edition=fundamental","pubTime":"2026-01-13 21:44","pubTimestamp":1768311852,"startTime":"0","endTime":"0","summary":"Polyrizon Ltd. 正将其初步发展重心，精准锁定于多个高增长潜力行业的运营公司。其战略布局尤其关注国防、航空以及人工智能等前沿领域。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLRZ"],"gpt_icon":0},{"id":"1109995262","title":"Polyrizon 向 FDA 提交 PL-16 病毒阻斷劑的前期指定請求，旨在減少對流感和感冒病毒的暴露","url":"https://stock-news.laohu8.com/highlight/detail?id=1109995262","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1109995262?lang=zh_tw&edition=fundamental","pubTime":"2025-12-19 21:20","pubTimestamp":1766150456,"startTime":"0","endTime":"0","summary":"Polyrizon 向 FDA 提交 PL-16 病毒阻断剂的前期指定请求，旨在减少对流感和感冒病毒的暴露。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLRZ"],"gpt_icon":0},{"id":"1122590563","title":"Polyrizon宣佈良好的滲透動力學，支持其鼻用納洛酮水凝膠項目的推進","url":"https://stock-news.laohu8.com/highlight/detail?id=1122590563","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1122590563?lang=zh_tw&edition=fundamental","pubTime":"2025-12-11 21:15","pubTimestamp":1765458914,"startTime":"0","endTime":"0","summary":"Polyrizon宣布良好的渗透动力学，支持其鼻用纳洛酮水凝胶项目的推进","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLRZ"],"gpt_icon":0},{"id":"1118176425","title":"Polyrizon發布與市場上市的鼻用納洛酮產品相比的積極粘附性結果","url":"https://stock-news.laohu8.com/highlight/detail?id=1118176425","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1118176425?lang=zh_tw&edition=fundamental","pubTime":"2025-12-03 22:29","pubTimestamp":1764772150,"startTime":"0","endTime":"0","summary":"Polyrizon发布与市场上市的鼻用纳洛酮产品相比的积极粘附性结果","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLRZ"],"gpt_icon":0},{"id":"1108302800","title":"Polyrizon宣佈按1至6的比例進行普通股反向拆分 - SEC文件","url":"https://stock-news.laohu8.com/highlight/detail?id=1108302800","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1108302800?lang=zh_tw&edition=fundamental","pubTime":"2025-11-25 21:05","pubTimestamp":1764075912,"startTime":"0","endTime":"0","summary":"Polyrizon宣布按1至6的比例进行普通股反向拆分 - SEC文件","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLRZ"],"gpt_icon":0},{"id":"2583063750","title":"Polyrizon Ltd.盤中異動 股價大跌6.41%報0.721美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2583063750","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583063750?lang=zh_tw&edition=fundamental","pubTime":"2025-11-14 22:30","pubTimestamp":1763130625,"startTime":"0","endTime":"0","summary":"北京时间2025年11月14日22时30分，Polyrizon Ltd.股票出现异动，股价快速下挫6.41%。截至发稿，该股报0.721美元/股，成交量2.8445万股，换手率0.47%，振幅2.47%。Polyrizon Ltd.股票所在的生物技术行业中，整体涨幅为0.00%。其相关个股中，Cidara Therapeutics, Inc.、Aspire Biopharma Holdings, Inc.、Invivyd, Inc.涨幅较大，Aspire Biopharma Holdings, Inc.、Clearmind Medicine Inc.、Salarius Pharmaceuticals, Inc.较为活跃，换手率分别为686.43%、33.92%、25.30%，振幅较大的相关个股有Silo Pharma, Inc.、Precigen, Inc.、Fennec Pharmaceuticals Inc.，振幅分别为9.19%、7.25%、7.15%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202511142230259504b00d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202511142230259504b00d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PLRZ"],"gpt_icon":0},{"id":"1106685558","title":"Polyrizon Ltd.公布積極的臨牀前研究結果：Pl-14顯示出令人鼓舞的過敏原阻斷效果","url":"https://stock-news.laohu8.com/highlight/detail?id=1106685558","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1106685558?lang=zh_tw&edition=fundamental","pubTime":"2025-10-06 20:22","pubTimestamp":1759753369,"startTime":"0","endTime":"0","summary":"Polyrizon Ltd.宣布其候选药物Pl-14在临床前研究中取得积极进展，该药物在过敏原阻断方面展现出令人鼓舞的疗效表现。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLRZ"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":12,"code":"91000000","status":"200"}]}}